Astrazeneca Aims to Almost Double Sales to $80 Billion by 2030

The Ideal AstraZeneca CandidateПодробнее

AstraZeneca sets ambition to deliver $80 billion annual by 2030Подробнее

AstraZeneca ups profit outlookПодробнее

AstraZeneca CEO says they've reduced emissions by 60%Подробнее

AstraZeneca will deliver nine million additional vaccine doses to EUПодробнее

AstraZeneca Lifts Guidance as Demand for Cancer Drugs GrowsПодробнее

Farewell to London & 3 x 3 million barrels day of too much oilПодробнее

AstraZeneca aims for $80 bln in total revenue by 2030 | REUTERSПодробнее

Global Electricity Demand to Double in Next 20 Years, Actis Chairman SaysПодробнее

AstraZeneca to buy Alexion Pharmaceuticals in $39 billion dealПодробнее

Accuray @ ASTRO 2024 - Interview with Rami El ShafieПодробнее

AstraZeneca buying drug developer Alexion for $39 billionПодробнее

AstraZeneca Shares Jump Most Since 2020Подробнее

AstraZeneca vaccine turns profitableПодробнее

AstraZeneca lifts 2024 outlook, doubles down on US plans | REUTERSПодробнее

AstraZeneca reports vaccine sales of $275 millionПодробнее

Hydrogen, AI, and Oil Outlook: CERAWeek 2024's Biggest Energy Takeaways | AlphaSenseПодробнее

We're in a difficult business but have the right level of confidence, says AstraZeneca CEOПодробнее

AstraZeneca shares dip after $39 bln Alexion dealПодробнее